Frontiers in Immunology (Jul 2022)
Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment
- Raquel Lopes,
- Raquel Lopes,
- Joana Caetano,
- Joana Caetano,
- Joana Caetano,
- Filipa Barahona,
- Filipa Barahona,
- Carolina Pestana,
- Carolina Pestana,
- Bruna Velosa Ferreira,
- Bruna Velosa Ferreira,
- Bruna Velosa Ferreira,
- Diana Lourenço,
- Diana Lourenço,
- Ana C. Queirós,
- Carlos Bilreiro,
- Carlos Bilreiro,
- Carlos Bilreiro,
- Noam Shemesh,
- Hans Christian Beck,
- Ana Sofia Carvalho,
- Rune Matthiesen,
- Bjarne Bogen,
- Bruno Costa-Silva,
- Karine Serre,
- Emilie Arnault Carneiro,
- Cristina João,
- Cristina João,
- Cristina João
Affiliations
- Raquel Lopes
- Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal
- Raquel Lopes
- Faculty of Medicine, University of Lisbon, Lisbon, Portugal
- Joana Caetano
- Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal
- Joana Caetano
- Hemato-Oncology Department, Champalimaud Foundation, Lisbon, Portugal
- Joana Caetano
- Faculty of Medical Sciences, NOVA Medical School (NMS), Lisbon, Portugal
- Filipa Barahona
- Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal
- Filipa Barahona
- Faculty of Medical Sciences, NOVA Medical School (NMS), Lisbon, Portugal
- Carolina Pestana
- Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal
- Carolina Pestana
- Centre of Statistics and Its Applications, Faculty of Sciences, University of Lisbon, Lisbon, Portugal
- Bruna Velosa Ferreira
- Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal
- Bruna Velosa Ferreira
- Hemato-Oncology Department, Champalimaud Foundation, Lisbon, Portugal
- Bruna Velosa Ferreira
- Faculty of Medical Sciences, NOVA Medical School (NMS), Lisbon, Portugal
- Diana Lourenço
- Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal
- Diana Lourenço
- Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- Ana C. Queirós
- Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal
- Carlos Bilreiro
- Faculty of Medical Sciences, NOVA Medical School (NMS), Lisbon, Portugal
- Carlos Bilreiro
- Neural Plasticity and Neural Activity Laboratory, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal
- Carlos Bilreiro
- Radiology Department, Champalimaud Foundation, Lisbon, Portugal
- Noam Shemesh
- Neural Plasticity and Neural Activity Laboratory, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal
- Hans Christian Beck
- Centre for Clinical Proteomics, Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark
- Ana Sofia Carvalho
- 0Computational and Experimental Biology, Chronic Diseases Research Centre (CEDOC); NOVA Medical School (NMS), Lisbon, Portugal
- Rune Matthiesen
- 0Computational and Experimental Biology, Chronic Diseases Research Centre (CEDOC); NOVA Medical School (NMS), Lisbon, Portugal
- Bjarne Bogen
- 1Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway
- Bruno Costa-Silva
- 2Systems Oncology, Champalimaud Physiology and Cancer Programme, Champalimaud Foundation, Lisbon, Portugal
- Karine Serre
- 3Molecular Medicine Institute-Laço Hub, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal
- Emilie Arnault Carneiro
- Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal
- Cristina João
- Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal
- Cristina João
- Hemato-Oncology Department, Champalimaud Foundation, Lisbon, Portugal
- Cristina João
- Faculty of Medical Sciences, NOVA Medical School (NMS), Lisbon, Portugal
- DOI
- https://doi.org/10.3389/fimmu.2022.909880
- Journal volume & issue
-
Vol. 13
Abstract
Multiple myeloma (MM), the third most frequent hematological cancer worldwide, is characterized by the proliferation of neoplastic plasma cells in the bone marrow (BM). One of the hallmarks of MM is a permissive BM microenvironment. Increasing evidence suggests that cell-to-cell communication between myeloma and immune cells via tumor cell-derived extracellular vesicles (EV) plays a key role in the pathogenesis of MM. Hence, we aimed to explore BM immune alterations induced by MM-derived EV. For this, we inoculated immunocompetent BALB/cByJ mice with a myeloma cell line, MOPC315.BM, inducing a MM phenotype. Upon tumor establishment, characterization of the BM microenvironment revealed the expression of both activation and suppressive markers by lymphocytes, such as granzyme B and PD-1, respectively. In addition, conditioning of the animals with MOPC315.BM-derived EV, before transplantation of the MOPC315.BM tumor cells, did not anticipate the disease phenotype. However, it induced features of suppression in the BM milieu, such as an increase in PD-1 expression by CD4+ T cells. Overall, our findings reveal the involvement of MOPC315.BM-derived EV protein content as promoters of immune niche remodeling, strengthening the importance of assessing the mechanisms by which MM may impact the immune microenvironment.
Keywords